HTB

Conference reports

Activists protest the price of sofosbuvir: “So-Valdi, So-Expensive” – UK access already rationed

EASL 2014: summary of interferon-free HCV studies with new DAAs

WHO launch treatment guidelines for hepatitis C (2014)

3rd Joint Conference of BHIVA/BASHH, 1-4 April 2014, Liverpool

50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice

PIVOT study: further analysis from five-year PI/r monotherapy strategy study

Sexually transmitted HCV in HIV positive and negative gay men

Annual HCV testing and use of core antigen to reduce costs and increase diagnosis during acute HCV

HIV positive attitudes to involvement as donors and recipients in organ transplant programmes

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

Pharmacokinetics of antiretrovirals in pregnancy

Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth

Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents

Early antiretroviral treatment in infants

Hospitalisation among elite controllers

Catching up with pathogenesis and cure research from CROI 2014

21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston

No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up

PrEP injections every three months may protect against exposure from anal sex

ARV pipeline: doravirine, GSK-744 and BMS-068

Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study

Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r

Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257

Pharmacokinetic targets for efavirenz might be too high

Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART

Lower newborn bone mineral content with maternal tenofovir use

Paediatric pipeline: CROI 2014 update on new antiretrovirals for children

Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis

Xpert TB test has important advantages but does not reduce morbidity

Reports of a second baby possibly cured of HIV: uncertainty remains

Updates on SB728-T, a CCR5-targeting gene therapy

4th International Workshop on HIV & Women, 13-14 January 2014, Washington

Women, HIV research and antiretrovirals

Improved virological outcomes for women starting efavirenz-based first-line regimens in South Africa

High rates of pregnancy in HIV positive women in Zambia and South Africa

Contraceptive choices among a Canadian cohort of HIV positive women

Bone disease and older HIV positive women

Lower immune response to the qHPV vaccine in HIV positive girls

HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study

Outcomes in infants exposed to lopinavir/ritonavir in utero

17th International Conference on AIDS and STIs in Africa (ICASA), 7-11 December 2013, Cape Town

Two percent rate of efavirenz discontinuation in an ART programme in Malawi

6th International Workshop on HIV Persistence During Therapy, 3-6 December 2013, Miami, USA

Report from the 6th Workshop on HIV Persistence

44th Union World Conference on Lung Health, 30 October – 3 November 2013, Paris

Preventing and treating TB in children – more baby steps

14th European AIDS Conference (EACS), 16-19 October 2013, Brussels

Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study

GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections

Cenicriviroc: 48 week results compared to efavirenz

Approaches to once-daily raltegravir: new formulation likely to require food

DSMB stops boosted atazanavir monotherapy study due to virological failure

Recreational drug use is common in HIV positive gay men and is extensive in a significant minority

Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk

Osteoporosis triples risk of later fracture in 1000-person US HIV group

Bone turnover marker changes early in ART predict bone loss after 96 week

Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison

Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged

53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver

Raltegravir safe and effective in pregnancy in small French study

Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy

Good safety profile with long-acting integrase inhibitor GSK744

TAF comparable to TDF in once-daily pill for ART-naive: 48-week results

Post navigation